EPIC-HR
Nirmatrelvir-Ritonavir in High-Risk Outpatients with COVID-19
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 2,246 high-risk unvaccinated adults with COVID-19, nirmatrelvir-ritonavir within 5 days of symptom onset reduced COVID-19-related hospitalisation or death by day 28 compared with placebo.
N
2.246
Design
Double-blind RCT
Endpunkt
Hospitalisation or death at 28 days
Relevanz
2
Ergebnis0.77 % vs 6.31 %; ~89 % relative reduction.
Hammond J, et al. N Engl J Med. 2022;386(15):1397-1408. 10.1056/NEJMoa2118542
Diskussion & Kritik
Cornerstone outpatient antiviral — caveat: efficacy in vaccinated lower-risk patients and drug-drug interactions limit real-world impact.